Standout Papers

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed o... 2020 2026 2022 2024279
  1. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study (2020)
    Meletios Α. Dimopoulos, Hang Quach et al. The Lancet

Immediate Impact

1 by Nobel laureates 60 standout
Sub-graph 1 of 22

Citing Papers

Definition, classification and diagnosis of pulmonary hypertension
2024 Standout
Fundamentals of redox regulation in biology
2024 Standout
2 intermediate papers

Works of Zandra Klippel being referenced

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2020 Standout
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
2019

Author Peers

Author Last Decade Papers Cites
Zandra Klippel 492 504 422 32 758
M. Ronald Schaafsma 347 495 392 22 747
Adam Waxman 456 514 405 30 890
M N Chang 261 387 265 20 938
Christine M. Segeren 275 489 360 20 695
PJ Burke 363 374 410 26 802
Nanao Kamada 181 267 344 27 767
Bruno Anglaret 389 292 184 30 743
Khalid Mezzi 408 477 394 26 748
Jennifer Treleaven 254 443 200 28 695
Simon Bomken 361 232 368 32 931

All Works

Loading papers...

Rankless by CCL
2026